Mycophenolate mofetil is an immunosuppressant used to prevent organ rejection in adult and pediatric patients aged three months and above who have undergone kidney, heart or liver transplants. The drug is administered in combination with other immunosuppressive therapies.
According to industry estimates cited by the company, the US market for Mycophenolate Mofetil is valued at approximately $30 million.
The approval is expected to strengthen Concord Biotech’s product portfolio in the US market and create additional growth opportunities in the transplant therapeutics segment.
The company said the nod aligns with its long-term strategy of expanding its presence across regulated international markets.
Concord Biotech shares ended Tuesday’s session 11.18% higher at ₹1,180. Despite the sharp rally, the stock remains down about 12% so far in 2026.
First Published: Jun 3, 2026 9:10 AM IST
